Award recognises and rewards journalism that extends public awareness and understanding of COPD
- Details
- Category: Boehringer Ingelheim
The independent judging panel of the Eloquium Award has today named three journalists as winners of the 2007 competition for excellence in reporting on chronic obstructive pulmonary disease (COPD) the fastest growing cause of death in the world's most advanced economies. Currently, 600 million people live with COPD which is projected to become the worldâs third-leading cause of death by 2020.[1,2]
Roche signs licensing and settlement agreements for Hepatitis C immunodiagnostics
- Details
- Category: Roche
Roche announced licensing and settlement agreements with Ortho-Clinical Diagnostics, Inc. and Novartis Vaccines & Diagnostics in the field of Hepatitis C Virus (HCV) Diagnostics. Under the terms of the licensing agreement Ortho-Clinical Diagnostics, Inc. and Novartis Vaccines & Diagnostics granted Roche Diagnostics a worldwide royalty-bearing license under their broad patent portfolio for Hepatitis C Virus (HCV) in the field of immunodiagnostics.
Novo Nordisk celebrates first ever UN-observed World Diabetes Day
- Details
- Category: Novo Nordisk
14 November is World Diabetes Day (WDD). This year is the first time that WDD is officially recognised by the United Nations. Novo Nordisk is celebrating the day with activities all over the world, from the UN building in New York to the pyramids of Egypt.
Novel agent for treatment of Parkinson's disease in clinical development
- Details
- Category: Lundbeck
Lundbeck has initiated phase I clinical trials with the pharmaceutical candidate Lu AA47070 to investigate safety, tolerability and the pharmacokinetic profile of the compound in humans. Lu AA47070 is a novel adenosine receptor antagonist that has been shown to be efficacious in a number of animal models for neurological diseases including models of Parkinson's disease.
New Phase III Trial Results for Rivaroxaban
- Details
- Category: Bayer
Findings from three phase III clinical trials will be presented in the plenary session and during oral presentations at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia, from December 8 to 11, 2007. The studies evaluated rivaroxaban in head-to-head comparison with enoxaparin, the current standard of care, for the prevention of venous thromboembolism (VTE) in patients undergoing major orthopaedic surgery.
Novo Nordisk launches Changing Diabetes Barometer
- Details
- Category: Novo Nordisk
At a media roundtable in Brussels, Novo Nordisk presented the Changing Diabetes Barometer, which will measure and share the worldwide progress in the fight against diabetes on an annual basis. The Barometer is a tool that will provide healthcare professionals, patient organisations, politicians, institutions and media with valuable information on how to improve the quality of diabetes care, bring down diabetes-related complications, extend patients' life expectancy and reduce costs.
Lipitor Demonstrated Significant Improvement or Stabilization of Kidney Function
- Details
- Category: Pfizer
Pfizer announced that post-stroke or mini-stroke patients treated with Lipitor® (atorvastatin calcium) Tablets 80 mg had stabilization or improvement in kidney function. These results were demonstrated in patients with or without chronic kidney disease, metabolic syndrome or type 2 diabetes. This post-hoc analysis of the landmark Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) study, was presented at the Annual Scientific Sessions of the American Heart Association.
More Pharma News ...
- Bayer Temporarily Suspends Global Trasylol® Marketing
- Novo Nordisk celebrates 75-year commitment to diabetes research
- Taisho and Pfizer Sign a Letter of Intent for Taishoâs Schizophrenia Drug Candidate
- Tasigna® receives US approval providing new hope to chronic myeloid leukemia patients
- Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension
- Nexavar® Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe
- Nycomed signs definitive agreement to acquire Bradley Pharmaceuticals, Inc.